“Making discoveries that directly impact and improve the lives of patients is incredibly fulfilling and meaningful work. It’s a reminder of the importance of scientific research and the potential it holds to create a better future for everyone.” Loud thoughts of a PI
Our lab is focused on testing the pharmacokinetics and pharmacodynamics (PK/PD) of antibiotics including new antibacterial agents, combination therapies, bacteriophages and lysins. We evaluate PK/PD parameters by designing and operating in vitro models of various diseases such as bacteremia, infective endocarditis and bone/ joint infections. One of our goals is to achieve dose de-escalation of antibiotics using various strategies such as combination treatments. Some of the interesting features of our in vitro models include, flexibility of duration, bacterial burden and sampling/resistance/tolerance testing. Additionally, these models are employing humanized doses of antibiotics using relevant pharmacokinetic calculations such as half life, release rate, etc. This is especially important for antibiotics with multiple side effects or antibiotics with elevated resistance profile. In our recent research work we proposed to combine two standard of care antibiotics (one dose of each) to create an excellent outpatient strategy and prevent extended hospital stay and/or emergence of resistance.
Funding Sources:
Copy right 2024-P3 Research Laboratory-All rights reserved.
